(RSPH) Invesco SP500 Equal Weight - Ratings and Ratios
Health, Pharmaceutical, Biotechnology, Medical, Devices
Dividends
| Dividend Yield | 0.71% |
| Yield on Cost 5y | 0.92% |
| Yield CAGR 5y | -36.93% |
| Payout Consistency | 89.6% |
| Payout Ratio | - |
| Risk via 5d forecast | |
|---|---|
| Volatility | 14.6% |
| Value at Risk 5%th | 23.9% |
| Relative Tail Risk | -0.25% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.17 |
| Alpha | -5.37 |
| CAGR/Max DD | 0.26 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.348 |
| Beta | 0.606 |
| Beta Downside | 0.599 |
| Drawdowns 3y | |
|---|---|
| Max DD | 17.13% |
| Mean DD | 5.59% |
| Median DD | 4.94% |
Description: RSPH Invesco SP500 Equal Weight October 21, 2025
The Invesco S&P 500 Equal Weight Health Care ETF (RSPH) seeks to track an equal-weight version of the S&P 500 health-care segment, investing at least 90 % of its assets in the constituent securities of that index as defined by GICS. By weighting each health-care company equally, the fund reduces concentration risk relative to market-cap-weighted peers.
Key metrics to watch: the fund’s expense ratio sits at 0.30 %, and its top ten holdings (as of the latest filing) include UnitedHealth Group, Johnson & Johnson, and Pfizer, each representing roughly 1 % of assets-far below the 5-10 % weights typical in cap-weighted health-care ETFs. Recent quarterly data show the ETF delivering a 7.2 % total return YTD, outpacing the broader S&P 500’s 5.8 % YTD performance, driven by strong earnings growth in biotech and rising demand for outpatient services amid an aging U.S. population.
Given the sector’s sensitivity to Medicare policy changes and R&D pipelines, monitoring FDA approval rates and federal health-care spending trends can provide early signals for RSPH’s upside or downside; for a deeper quantitative dive, you may find ValueRay’s sector analytics useful.
What is the price of RSPH shares?
Over the past week, the price has changed by +0.41%, over one month by +1.72%, over three months by +9.87% and over the past year by +6.20%.
Is RSPH a buy, sell or hold?
What are the forecasts/targets for the RSPH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 32.7 | 2.3% |
RSPH Fundamental Data Overview December 02, 2025
Beta = 1.03
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 772.5m USD (772.5m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 772.5m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 772.5m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.25% (E(772.5m)/V(772.5m) * Re(8.25%) + (debt-free company))
Discount Rate = 8.25% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for RSPH ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle